List of technologies available for licencing or transfer

Technology Transfer Office

LIST OF TECHNOLOGIES AVAILABLE FOR LICENSING - thematic filing

MEDICAL APPLICATION RESEARCH TOOLS INDUSTRIAL APPLICATION
Diagnostics
  • Markers-other
  • Markers-genetic
  • Markers-proteoic
  • Infectious diseases-Bacterial
  • Infectious diseases-Viral 
  • Other diseases (non infect)
  • Methods-other
  • Methods-Antibody
  • Methods-Biochip
  • Methods-Detection
  • Methods-Device
  • Methods-Imaging
  • Methods-Immunoassay
  • Industrial
Therapeutics
  • Allergy 
  • Antibiotics
  • Antivirals
  • Apoptosys               
  • Bacterial infection-other
  • Bacterial infection-Tuberculosis
  • Cancer
  • Cell signalling
  • Cardiovascular
  • Central nervous system
  • Disease transmission (Anopheles)
  • Disease model
  • Drug delivery
  • Drug design
  • Fungi Fungal infection?
  • Pain control (Analgesic)
  • Pathogen
  • Peptides
  • Parasitology-other
  • Parasitology-Malaria
  • Vaccines
  • Viral infection-other
  • Viral infection-Hepatitis
  • Viral infection-VIH HIV
  • Gene therapy
  • Immunotherapy
  • Inflammation
Animal models
  • Mouse models
  • Other animal model
Bio-informatics

Biological material / life sciences

  • Antibody
  • Protein
  • Cell line
  • DNA/RNA
  • enzyme
  • Vector
  • library
Imaging

Processes, techniques, screening
  • molecular evolution
  • protein expression
  • sequencing
  • microarray
  • culture
  • synthesis
  • Drug discovery (Comp Lib)
  • Formulation
  • genetics
Agribusiness

Environmental

Hygiene

Manufacturing

Probiotics

Vetenary medicine


Allergy

Allergy
D.I. n° Inventor Title

01.77        

Salah MECHERI

A humanized mast cell system for the detection of functional human IgE : use for the detection of anaphylactogenic and anti-anaphylactogenic substances (biological material)

98.44

Ulrich BLANK

A humanized mast cell system fixing IgE

Agribusiness

Agribusiness  
D.I. n°  Inventor Title

00.44     

Bernard DUJON

Microsatellite typing kit for the identification of yeast strains: food testing and human diagnostic applications

96.53

Robert LONGIN

91.16

Patrick GRIMONT

Probes for 16 S RNA : detection of E. Coli or Shigella

Agrochemicals

Agrichemicals
D.I. n°  Inventor Title

00.07

Bernard DUJON

Photorhabdus luminescens genome (TT01 strain)                                           

96.53

Robert LONGIN

91.16

Armelle DELECLUSE

Animal model

Animal model
D.I. n° Inventor Title

00.48

Jean-Pierre CHANGEUX

Alpha6 nAChR subunit Knockout Mouse Model (ACNA6)

98.01

Jean-Pierre CHANGEUX

Alpha4 nAChR subunit Knockout Mouse Model (ACNA4)

Biochemistry

Biochemistry
D.I. n° Inventor Title
05.52 David PRANGISHVILI The thermostable DNA polymerase from a virus of the hyperthemophilic archaeon Acidianus

01.58

Liliane ASSAIRI

Use of recombinant NAD kinase from bacillus subtilis and Neisseria meningitidis for the synthesis of NADP

00.31/98.20

Philippe MARLIERE In vivo production of proteins chemically diversified by incorporation of non-conventional amino acids: useful in vaccines, therapy, diagnosis and biocynthesis
00.29 Michel VERON In vivo and in vitro synthesis of nucleoside triphosphate analogs using mutant nucleoside diphosphate kinase (NDPK)

BioInformatics

BioInformatics 
D.I. n°  Inventor Title

04.31

Didier MAZEL

Modulating mutational frequency to optimize protein evolution

02.48

Alexis COLLETTE

ISEApeaks :a strategy for global and statistical immune repertoire analysis. Use of the ISEApeaks software program as a tool in disease diagnosis and prognosis

02.03

Farid CHETOUANI

DiffTool: bulding, visualizing and querying protein clusters
01.45 Farid CHETOUANI Find Target: a software tool for subtractive genome analysis
01.43 Lionel FRANGEUL GMP-Tool-Box: a software package for bacterial genome sequencing projects from shotgun follow-up to annotation
00.54 Edouard YERAMIAN Computational method for enhanced detection of genes and coding regions within long genomic sequences
99.92 Adrien SIX A new software package to contribute to a comprehensive automation of immune repertoire analysis
96.12 Patrick GRIMONT
Taxotron software for the automatic identification of bacteria

Biological Material

Biological Material / Life sciences 
 D.I. n°  Inventor Title
05.52 David PRANGISHVILI The thermostable DNA polymerase from a virus of the hyperthemophilic archaeon Acidianus
05.40 Simon WAIN-HOBSON Recovery of APOBEC3-edited human immunodeficiency virus G A hypermutants by differential DNA denaturation PCR
05.39 Simon WAIN-HOBSON Recovery of APOBEC3-edited human immunodeficiency virus G A hypermutants by differential DNA denaturation PCR

04.97/04.06/
98.03

Philippe BRULET

Use of the CA2+ reporter GFP-aequorin for probing infection and physiology

04.90-02.91 Annette MARTIN Chimeric GB virus B (GBV-B) : use in the development of treatments targeting Hepatitis C virus infection
04.31 Didier MAZEL Modulating mutational frequency to optimize protein evolution
04.17 Armelle PHALIPON Production and characterization of murine monoclonal antibodies specific for lipopolysaccharide and protecting against Shigella flexneri serotype 2a for (i) development of a diagnostic kit and (ii) characterization of known oligoside epitopes that could serve as the basis of a chemically-defined synthetic vaccine.
04.14 Frédéric TANGY Infectious flavivirus pseudo-particles containing functional prM-E envelop proteins
04.12 Philippe DESPRES Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis
03.91 Vincent DEUBEL Novel golden Hamster model for henipavirus (Nipah-Hendra) infection
03.64 Lena EDELMAN Anti-GPIV monoclonal antibodies
03.27 Pierre CHARNEAU Non transformed cultured lines of embryonic mouse hepatic stem cells able to repopulate the mouse liver and ifferentiate into hepatocytes and bile ducts in vivo
02.118 Mireille MONTEBEYRIE Monoclonal antibodies directed against the c-terminal end of the protein P2 ribosomal of Trypanosoma cruzi
02.104 Nancy GUILLEN Entamoeba histolytica strain overexpressing the catalytic domain of protein kinase EhPAK
02.100 Faridabano NATO Production of specific monoclonal antibodies against subunits A and B of cholera toxin (Biological Material)
02.85 Jean-Pierre CHANGEUX CGRP in the treatment of nicotine withdrawal syndrome : transgenic mouse model
01.13/02.57 Alphonse GARCIA Novel targeting peptides for intracellular delivery of compounds: research and therapeutic applications
02.60 Farida NATO Rapid diagnosis of cholera based on immunochromatography
02.59 Anne BLANCHARD Development and characterization of two monoclonal antibodies directed against the 15 C-terminal amino acids of aquaporin-2 and their evaluation using histologic sections of kidney from various species (human, rat, mouse)
02.08 Ara HOVANESSIAN Hybridoma cell lines : 71/10 against the proteine kinase PKR ; 56/3 against the 2-5A synthetase 69 kDa ; 25/11 against the 2-5A synthetase 100 lDa
01.77 Salah MECHERI A humanized mast cell system for the detection of functional human IgE : use for the detection of anaphylactogenic and anti-anaphylactogenic substances
01.76 Franck KUNST Mise en évidence de composés ou de toxines produites par Photorhabdus luminescens au moyen de l’amibe Dictyostelium discoideum
01.32 Isabelle SAINT-GIRON Restriction-modification system in Leptospira biflexa clone patoc 1 (biological material)
01.20 James DI SANTO Novel strain of alymphoid mice for xenotransplantation
00.59 Claude LECLERC B. pertussis adenylate cyclase-activating peptide receptor and its use in screening for immunologically/pharmacologically active molecules
00.29 Michel VERON In vivo and in vitro synthesis of nucleoside triphosphate analogs using mutant nucleoside diphosphate kinase (NDPK)
00.05 Christophe D’ENFERT cDNA library from Aspergillus nidulans for cloning of genes by functional complementation in S. cerevisiae yeast
98.44 Anna WEYER A humanized mast cell system fixing human IgE: Use for screening of immunological and chemical reagents endowed with anaphylactogenic or anti-degranulating properties
98.40 Jean-Marc CAVAILLON Hybridoma of anti-IL1 receptor antagonist
98.17 Fernando ARENZANA-SEISDEDOS Monoclonal antibodies anti-SDF1 hybridomas

Cancer

Cancer
D.I. n° Inventor Title
05.49 Sylvie BAY MUC6-Tn glycoconjugates mimicking cancer cells: applications to anti-tumor immunotherapy
04.107 Matthew ALBERT Prostaglandin E2 induces indoleamine 2.3 deoxygenase expression and works in synergy with TNF-SF and TLR ligands to trigger its activity

03.88

Fabrice AGOU

Functional characterization of minimal oligomerization domain of NEMO

03.83

Marie-Annick BUENDIA

Transgenics mice representing animal models of liver carcigenesis

03.68

Hervé BOURHY

Identification of a peptide motif of lyssavirus matrix protein involved in the induction of apoptosis : therapeutic applications
03.53 Claude LECLERC Synthetic glycopeptide vaccines : applications in anti-tumoral immunotherapy
03.32 Yu-Chun LONE Generation of mice that are doubly transgenic for HLA-A21 HLA-DR1 and doubly knocked-out for H-2 class 1 et Il (b2mO r Ilabo rKO) for the preclinical development of new vaccines
03.13 Jean-Michel THIBERGE Simplified method for molecular typing of Helicobacter pylori (H. pylori) isolates
01.13/02.57 Alphonse GARCIA Novel targeting peptides for intracellular delivery of compounds: research and therapeutic applications
02.76/02.84 Alphonse GARCIA Protein phosphatase 2A (PP2A)-targeting peptides designed for intracellular transfer and anti-apoptotic activity
02.70 Eric PRINGAULT In vitro model system for the study of prevention of dysplasias and adenocarcinomas arising from the intestinal metaplasias of Barrett’s syndrome
02.57 Alphonse GARCIA Intracellular transfer of protein phosphatase 2A (PP2A)-targeting peptides: novel strategy for the inhibition of tumoral and infectious processes
01.62 Alphonse GARCIA Protein Phosphatase 2A-chemokine receptor CXCR4, CC-5 and CD28 binding sites: novel targets for inhibition of HIV infection and tumor development
00.03 Philippe DESPRES Apoptotic sequence
96.61/99.62 Claude LECLERC MAG: A new family of optimized synthetic glycopeptidic vaccines with high therapeutic activity
96.42/95.33 Claude LECLERC Recombinant parvovirus-like particles for inducing cytotoxic T-cell response: use in antiviral and antitumoral drugs or vaccines

Diagnostics - Biomarckers

Diagnostics - Biomarkers
D.I. n° Inventor Title

08.90  

Marie-Annick BUENDIA

 Molecular markers of hepatocellular carcinoma: uses for prognosis and as potential therapeutic targets

08.71

Catherine ROUGEOT

Opiorphin, as a biomarker. Development and validation of a competitive ELISA for Opiorphin to establish its quantitative profile of secretion and distribution in human

Diagnostics - Environment / Industry

Diagnostics - Environment / Industry
D.I. n° Inventor Title

08.68  

Carmen Buchrieser

Molecular typing and diagnostic of Legionella pneumophila and Legionella longbeachae: Identification of marker genes and specific probes for simultaneous identification of the species and the serogroup in the environment and the patient

Diagnostics - Infections diseases

Diagnostics - Infections diseases
 D.I. n°  Inventor Title
09.17 Vincent ENOUF Molecular test for the detection of Influenza A virus subtype H1N1.
08.68 Carmen BUCHRIESER Molecular typing and diagnostic of Legionella pneumophila and Legionella longbeachae: Identification of marker genes and specific probes for simultaneous identification of the species and the serogroup in the environment and the patient
08.31 Hugues BEDOUELLE Simplified serological assays of infections by flaviviruses and other viruses, using hybrids between a viral protein domain and alkaline phosphatase
05.35 Suzanne CHANTEAU New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y.
04.32 Ralf ALTMEYER Optimized genes for increased SARS Co V Spike protein expression
04.14 Frédéric TANGY Infectious flavivirus pseudo-particles containing functional prM-E envelop proteins
04.12 Philippe DESPRES Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis
03.101 Philippe GLASER Complete sequence of Listeria monocytogenes strain CLIP80459. Use in genomic typing of Listeria monocytogenes and risk assessment
03.78 Patrick GRIMONT Molecular approach for capsular typing of Klebsiella
03.75 Claude LECLERC Recombinant CyaA toxins : diagnostic and immunomonitoring applications
03.33 Dana PHILPOTT Sensing of a unique muropeptide gram-negative bacterial peptidoglycan (PGN) by Nod1: drug screening, diagnostic and therapeutic applications
03.13 Jean-Michel THIBERGE Simplified method for molecular typing of Helicobacter pylori (H. pylori) isolates
03.04 Sylvie BAY Phosphorylcholine-glycoconjugates and their synthesis : diagnostic and therapeutic applications
02.122 Pascale COSSART Use of Listeria bile salt hydrolase to develop detection, diagnostic and therapeutic tools
02.118 Mireille MONTEBEYRIE Monoclonal antibodies directed against the c-terminal end of the protein P2 ribosomal of Trypanosoma cruzi
02.60 Farida NATO Rapid diagnosis of cholera based on immunochromatography
02.56 Jean-Marc GHIGO Identification of an external membrane protein family involved in interbacterial interactions during biofilm formation and conjugative transfer of genes: applications in the development of bacteria-BioR biofilm control procedures
02.30 Michèle BOULOY Recombinant antigen for the serological diagnosis of Puumala hantavirus infection
02.10 Stewart COLE Specifically deleted tubercular bacillus sequences for the rapid identification of M. tuberculosis and other members of the M. tuberculosis complex
01.63 Antoine DANCHIN Partial sequencing and annotation of Penicllium marneffei genome
01.47 Brigitte GICQUEL Probes for the identification of M. tuberculosis strains with accrued virulence and capable of housing or leading to the acquisition of antibiotic resistance genes
01.41 Christophe d’ENFERT Specific probes of Candida albicans yeast genome
00.75 Suzanne CHANTEAU Simple and rapid diagnosis of human plague
00.44 Bernard DUJON Microsatellite typing kit for the identification of yeast strains: food testing and human diagnostic applications
00.43 Bernard DUJON Novel nucleotide sequences of Saccharomyces cerevisiae and their use in the detection of hemiascomycetous yeasts
00.25 Gilles MARCHAL Immunogenic glycopeptides derived from Mycobacterium tuberculosis: diagnostic and vaccine applications
98.51 Stewart COLE Deleted sequences in M. bovis BCG/M. bovis or M. tuberculosis genomes: diagnostic and vaccine applications
98.31 Brigitte GICQUEL New sequences of M. tuberculosis and the identification of associated genes
97.44 Stewart COLE Genomic analysis method for the detection and identification of mycobacteria
96.07 Patrick GRIMONT Probes for 16 S RNA : detection of E. Coli or Shigella
91.13 Gilles MARCHAL Mycobacterium Proteins and their applications (naxi test)

Diagnostics - Methods

Diagnostics - Methods
D.I. n° Inventor Title

05.40 

Simon WAIN-HOBSON

Recovery of APOBEC3-edited human immunodeficiency virus A G hypermutants by differential DNA denaturation PCR

05.39

Simon WAIN-HOBSON

Recovery of APOBEC3-edited human immunodeficiency virus G A hypermutants by differential DNA denaturation PCR
02.48 Alexis COLLETTE ISEApeaks :a strategy for global and statistical immune repertoire analysis. Use of the ISEApeaks software program as a tool in disease diagnosis and prognosis
01.22 Marie-Louise GOUGEON Novel cytofluorometric method for quantitation and characterization of cell-mediated cytotoxic activity
99.68/69 Hugues BEDOUELLE Novel antibody-based fluorescence biosensor using no additional reagents
97.49 Philippe METEZEAU Chromosomic laser microdissection: process for cytogenetics abnormalities detection

Diagnostics - Non Infections diseases


Diagnostics - Non Infections Diseases
D.I. n° Inventor Title
08.90 Marie-Annick BUENDIA Molecular markers of hepatocellular carcinoma: uses for prognosis and as potential therapeutic targets
08.71 Catherine ROUGEOT Opiorphin, as a biomarker. Development and validation of a competitive ELISA for Opiorphin to establish its quantitative profile of secretion and distribution in human

02.82   

François ROUGEON

HC antibodies and their derivatives obtained through the immunization of camelids against human beta -amyloid peptide: use in the diagnosis and treament of Alzheimer’s disease

00.11

Alain ISRAËL

Detection of mutations in Nemo gene: use in diagnosis of familial incontinentia pigmenti 
00.10 Huseyin FIRAT Hybridomas producing anti-HLA-H antibodies for the diagnosis of human hemachromatosis
98.30 Jean-Luc GUESDON Molecular diagnostic for prelingual deafness
97.32 Christine PETIT Polynucleotides for detecting a frequent mutation responsible for prelingual non-syndromic deafness in the connexin 26 gene

Environment

Environment
D.I. n°  Inventor Title

01.01

Pierre BEGUIN Sequence of Photorhabdus luminescens genome (TT01 strain)

Gene Therapy

Gene Therapy
D.I. n° Inventor Title
01.13/02.57 Alphonse GARCIA Novel targeting peptides for intracellular delivery of compounds: research and therapeutic applications
96.69 Pierre CHARNEAU Central DNA Flap Sequence for new Lentiviral Vectors
96.02 Denise PAULIN Promotor of the SM22 gene and its applications for cardiovascular gene therapy
94.32 Denise PAULIN Desmine Promotor and its applications for gene therapy

Genomics

Genomics
D.I. n°  Inventor Title

04.31

Didier MAZEL Modulating mutational frequency to optimize protein evolution
01.63 Antoine DANCHIN Partial sequencing and annotation of Penicllium marneffei genome
98.30 Jean-Luc GUESDON Molecular diagnostic for prelingual deafness
97.44 Stewart COLE Genomic analysis method for the detection and identification of mycobacteria

HIV

HIV
 D.I. n°  Inventor Title
05.40 Simon WAIN-HOBSON Recovery of APOBEC3-edited human immunodeficiency virus A G hypermutants by differential DNA denaturation PCR
05.39 Simon WAIN-HOBSON Recovery of APOBEC3-edited human immunodeficiency virus A G hypermutants by differential DNA denaturation PCR

02.111

Ara HOVANESSIAN A universal B-cell epitope vaccine against HIV infection
01.68 Fernando ARENZANA-SEISDEDOS Human langerin is the principal receptor expressed by Langerhans cells permitting HIV envelope glycoprotein binding
01.62 Alphonse GARCIA Protein Phosphatase 2A-chemokine receptor CXCR4, CC-5 and CD28 binding sites: novel targets for inhibition of HIV infection and tumor development
01.55 Pierre LANGLADE-DEMOYEN News HIV1 epitopics peptides
 01.20 James DI SANTO Une nouvelle souche de souris alymphoïde pour la xenotransplantation
 99.86 Olivier SCHWARTZ A screening method to identify new HIV inhibitors
 99.38 Ralf ALTMEYER A new method for rapid screening of drugs inhibiting HIV entry

Hygiene

Immunotherapy

Immunotherapy
D.I. n°  Inventor Title

02.46

Pierre DRUILHE Anti-MSP3 recombinant antibodies
02.30 Michèle BOULOY Recombinant antigen for the serological diagnosis of Puumala hantavirus infection
01.49 Salah MECHERI Determination of vaccine protective potential using mastocyte-activating salivary antigens from mosquitos
96.61/99.62 Claude LECLERC MAG: A new family of optimized synthetic glycopeptidic vaccines with high therapeutic activity

Inflammation


Neurobiology

Neurobiology
D.I. n°  Inventor Title

06.16

Pedro ALZARI A novel neurotrophin species linked to inflammation, chronic pain and neuropathology as a target for drug design and immunotherapy
04.97/04.06/
98.03
Philippe BRULET Use of the CA2+ reporter GFP-aequorin for probing infection and physiology
03.42 Benoit ROBERT Msx1 and Msx2 are required for the integrity and functionality of the dorsal roof plate of the neural tube, maintaining a non neuronal identity of the roof plate cells. Use in screening and identification of genes involved in differentiation, proliferation and maintainance of glial lineage
02.103 Thomas BOURGERON  Mutation of neuroligin HNL3 gene in autism and the identification of the sequence of MNL4, the gene ortholog of HNL4X in mouse
02.97 Daniel GONZALES-DUNIA 2’Fluoro-2’-deoxycytidine inhibits Borna Disease Virus Replication and Spread
02.85 Jean-Pierre CHANGEUX CGRP in the treatment of nicotine withdrawal syndrome : transgenic mouse model
02.82 François ROUGEON HC antibodies and their derivatives obtained through the immunization of camelids against human beta -amyloid peptide: use in the diagnosis and treament of Alzheimer’s disease
02.58 Jean-Michel HEARD Treatment of central nervous system lesions associated with lysosomal storage disease by intracerebral injection of AAV vectors
01.80 Jean-Pierre CHANGEUX Utilisation de souris mutantes pour la sous unité nicotinique beta 2 pour trier des molécules qui modulent les symptômes de sevrage à la nicotine
01.71 Jean-Claude MAZIE Mouse monoclonal antibody C11 58,2 directed against Tetanus neurotoxin-Insensitive Vesicle Associated Membrane Protein (TI-VAMP or SybL1p)
01.69 Mannich BUENDIA Beta-catenin and FHL2 interactions in Alzheimer disease: therapeutic applications
01.61 Thomas BOURGERON A frameshift mutation of HNL4, a primate specific X-linked neuroligin, is associated with autistic disorder and Asperger
00.49 Jean-Pierre CHANGEUX Transgenic mice with mutations of the beta2 subunit of the neuronal nicotinic acetylcholine receptor (nAChR)
00.48/98.01 Jean-Pierre CHANGEUX Mutant mice deleted for different nicotinic acetylcholine receptor subunits
00.21 Hoang-Oanh NGHIEM Purification of histidine kinase proteins and their use in phosphorylation of proteins involved in allergy

Processes

Processes
D.I. n° Inventor Title

04.32

Ralf ALTMEYER

Optimized genes for increased SARS Co V Spike protein expression

04.31

Didier MAZEL Modulating mutational frequency to optimize protein evolution
03.76 Armand BERNEMAN Screening procedure for potential inhibitors of proline racemase
02.56 Jean-Marc GHIGO Identification of an external membrane protein family involved in interbacterial interactions during biofilm formation and conjugative transfer of genes: applications in the development of bacteria-BioR biofilm control procedures
97.49 Philippe METEZEAU Chromosomic laser microdissection: process for cytogenetics abnormalities detection
96.53 Robert LONGIN MultiMicroFermentors

Proteomics

Proteomics
D.I. n° Inventor Title

04.31

Didier MAZEL

Modulating mutational frequency to optimize protein evolution

00.31/98.20

Philippe MARLIERE In vivo production of proteins chemically diversified by incorporation of non-conventional amino acids: useful in vaccines, therapy, diagnosis and biocynthesis
99.72 Yves JACOB Constrained peptides libraries for use in a combinatorial approach to selecting molecules of pharmacological interest
96.53 Robert LONGIN MultiMicroFermentors

Research tools

Research tools
D.I. n°  Inventor Title
09.25 Nicolas WOLFF Structural tools to design peptides promoting neuronal survival or apoptosis
08.88 Christophe PREHAUD Viral Polypeptide inducing neuron survival, polynucleotides encoding them and therapeutic uses thereof

00.45

Bernard DUJON

Specific primers from the Saccharomyces cerevisiae genome for the design of microarrays

97.44

Stewart COLE


Therapeutics anopheles

Therapeutics anophele
D.I. n° Inventeur Titre
05.35 Suzanne CHANTEAU New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y.

Therapeutics bacterial

Therapeutics bacterial
D.I. n° Inventor Title
04.27 Anthony PUGSLEY A novel antimicrobial target specific to Gram-negative bacteria
03.33 Dana PHILPOTT Sensing of a unique muropeptide gram-negative bacterial peptidoglycan (PGN) by Nod1: drug screening, diagnostic and therapeutic applications
03.13 Jean-Michel THIBERGE Simplified method for molecular typing of Helicobacter pylori (H. pylori) isolates
02.62 Elisabeth
CARNIEL
Identification of genes specifically expressed in Y pestis and Y pseudotuberculosis
02.28 Stewart COLE Novel antigens for the diagnosis, prevention and treatment of mycobacteriosis
01.82 Antoine DANCHIN
Identification of pharmacologic targets during methylthioribose (MTR) recycling and events involved in post-traduction modification of lysine residues by carbamylation
01.63 Antoine DANCHIN Partial sequencing and annotation of Penicllium marneffei genome
01.53 Maurice HOFNUNG "Big Blue" transgenic mice as animal models of chronic Helicobacter pylori infection and their use in the evaluation of the effects of therapeutic compositions on gastric mutagenesis 
00.26  Agnès LABIGNE  Genomic random library of H. pylori
00.01 Franck KUNST Sequence of Photorhabdus luminescens genome (TT01 strain)
98.08  Agnès LABIGNE UreI protein: a novel target for Helicobacter pylori eradication therapy
 

Therapeutics biofilm

Thérapeutics biofilm
D.I. n° Inventor Title

02.56

Jean-Marc GHIGO Identification of a family of external membrane proteins involved in interbacterial interactions during biofilm formation and conjugative gene transfer: use in the development of bacterial biofilm control strategies

Therapeutics cancer

Therapeutics Cancer
D.I. n° Inventeur Titre

04.02

François LEMONNIER Evaluation of the protective capacity of cellular immune response completely restricted to human HLA alleles induced in vivo in the absence of murine response competition in mice doubly transgenic for HLA-A2/HLA-DR1 and double knockout for H-2 class 1&II (b2m°/°/lab°/°KO) against viral challenge. Vaccine and immunology applications for preclinical development of new vaccines.
03.83 Marie-Annick BUENDIA Transgenics mice representing animal models of liver carcigenesis
03.68 Hervé BOURHY Identification of a peptide motif of lyssavirus matrix protein involved in the induction of apoptosis : therapeutic applications
02.76 Alphonse GARCIA
Protein phosphatase 2A (PP2A)-targeting peptides designed for intracellular transfer
and anti-apoptotic activity
02.57 Alphonse GARCIA Intracellular transfer of protein phosphatase 2A (PP2A)-targeting peptides: novel strategy for the inhibition of tumoral and infectious processes
01.62 Alphonse GARCIA Protein Phosphatase 2A-chemokine receptor CXCR4, CC-5 and CD28 binding sites: novel targets for inhibition of HIV infection and tumor development
96.61/99.62 Claude LECLERC MAG: A new family of optimized synthetic glycopeptidic vaccines with high therapeutic activity
96.42/95.33 Claude LECLERC Recombinant parvovirus-like particles for inducing cytotoxic T-cell response: use in antiviral and antitumoral drugs or vaccines

Therapeutics cardiovascular, hematology, thrombosis

Therapeutics cardiovascular, hematology, thrombosis
D.I. n° Inventor Title

03.12

Jean-François POULIN DNA construct for assessing thymic function activity and therapeutical uses thereof
02.86 Daniel SCOTT-ALGARA Novel therapy for the treatment of atherosclerosis and inflammatory processes induced by pathogenic agents
01.13/02.57 Alphonse GARCIA Novel targeting peptides for intracellular delivery of compounds: research and therapeutic applications
96.02 Denise PAULIN Promotor of the SM22 gene and its applications for gene therapy
  

Therapeutics central nervous system

Therapeutics central nervous system
D.I. n° Inventor Title
02.82 François ROUGEON HC antibodies and their derivatives obtained through the immunization of camelids against human beta -amyloid peptide: use in the diagnosis and treament of Alzheimer’s disease
02.44 Pierre LAFAYE Monoclonal antibodies directed against calreticulin: diagnostic and intracellular targeting applications
01.69 Mannich BUENDIA Beta-catenin and FHL2 interactions in Alzheimer disease: therapeutic applications
01.61 Thomas BOURGERON A frameshift mutation of HNL4, a primate specific X-linked neuroligin, is associated with autistic disorder and Asperger
99.36/85 François ROUGEON Bioactive peptides derived from submandibular rat 1 protein (SMR1) and its derivatives: therapeutic and diagnostic applications
 

Therapeutics compounds library

Thérapeutics Compouds library
D.I. n° Inventor Title

99.72

Yves JACOB Constrained peptides libraries for use in a combinatorial approach to selecting molecules of pharmacological interest

Therapeutics fungi

Therapeutics fungi
D.I. n° Inventor Title
01.56 Christophe d’ENFERT Method for the identification of genes required for the growth of filamentous Aspergillus fumigatus fungus: use in screening for new antifungal molecules
01.41 Christophe d’ENFERT Specific probes of Candida albicans yeast genome
96.68 Christophe d’ENFERT Strains of pyrG. Aspergillus fumigatus and their application in the screening of antifungals

Therapeutics hepatitis

Therapeutics Hepatitis
D.I. n° Inventor Title
06.53 Matthew L. ALBERT sIP-10, CD26 activity and responsiveness to therapy in chronic HCV patients
04.90-02.91 Annette MARTIN
Chimeric GB virus B (GBV-B) : use in the development of treatments targeting Hepatitis C virus infection
04.64 Agata BUDKOWSKA Cell entry of hepatitis C virus via human scavenger receptor hSR-BI. Screening for candidate therapeutic molecules capable of inhibiting HCV/SR-BI
04.29 Yves RIVIERES T-cell immunogenicity of protein core+ 1 in chronic carriers of hepatitis C virus. Therapeutic and/or vaccine applications
03.07 Ralf ALTMEYER Interaction of HCV glycoproteins with dendritic cell and liver endothelial call lectins DC-SIGN and L-SIGN
02.83 Catherine TRANSY
Molecular tools for the selection of human primary hepatocytes infected with hepatitis C virus (HCV): use in the development of novel antiviral molecules and in the study of molecular interactions between HCV and host cell
 

Therapeutics VIH

Therapeutics VIH
D.I. n° Inventor Title
04.47 Frédéric TANGY Anti-HIV-1 activity of dermaseptin S4, a broad spectrum antimicrobial: potential use as a local microbicide for the prevention of mucosal HIV transmission during sexual intercourse
01.68 Fernando ARENZANA-SEISDEDOS Human langerin is the principal receptor expressed by Langerhans cells permitting HIV envelope glycoprotein binding
99.86 Olivier SCHWARTZ A screening method to identify new HIV inhibitors 
99.38 Ralf ALTMEYER A new method for rapid screening of drugs inhibiting HIV entry

Therapeutics malaria


Therapeutics parasitology

Therapeutics parasitology
D.I. n° Inventor Title
03.76 Armand BERNEMAN Screening procedure for potential inhibitors of proline racemase
02.127 Paola MINOPRIO Crystallographic structure of Trypanosoma cruzi proline racemase
02.118 Mireille MONTEBEYRIE Monoclonal antibodies directed against the c-terminal end of the protein P2 ribosomal of Trypanosoma cruzi
02.04 Michel VERON Novel Plasmodium falciparum antigen DG 571 for the induction of protection against challenge infection with Plasmodium sporozoite
00.80 Hechmi LOUZIR Vaccine against leishmaniasis using virulence antigen P55 gene
00.19 Jüng GYSIN Novel proteins involved in cytoadhesion of Plasmodium falciparum-infected erythrocytes: diagnostic and vaccine applications
00.13 Isabelle TARDIEUX Therapeutic use of specific domains of toxofilin, a novel actin-binding protein from Toxoplasma gondii

Therapeutics pain

Therapeutics pain
D.I. n° Inventor Title
08.19 Catherine ROUGEOT New opiorphin (QRFSR) Peptide deritatives as potent dual inhibitor of enkephalin-degrading ectopeptidases
08.06 Catherine ROUGEOT Therapeutic applications of opiorphin, as -analgesic- anti-depressant psychostimulant molecule without the majour side-effects of morphine
08.05 Catherine ROUGEOT Palmitoyl - QRFSR - CONHZ EFFECT ON hNEP and hAP-N
08.02 Catherine ROUGEOT FRET - Based enzyme in vitro models - Validation on hNEP & hAP-N activity - Effect of Orpiophin derivatives

06.16

Pedro ALZARI A novel neurotrophin species linked to inflammation, chronic pain and neuropathology as a target for drug design and immunotherapy
99.36/85 François ROUGEON Bioactive peptides derived from submandibular rat 1 protein (SMR1) and its derivatives: therapeutic and diagnostic applications.

Therapeutics tuberculosis

Therapeutics tuberculosis
D.I. n° Inventor Title
04.109 Stewart COLE Pyranodibenzofuran derivatives with antifungal and bacterial activity
02.28 Stewart COLE Novel antigens for the diagnosis, prevention and treatment of mycobacteriosis 
02.26 Brigitte GICQUEL Recombinant Mycobacterium bovis BCG (rBCG) strains expressing chicken ovalbumin (ova) gene included within replicating or integrating vectors
02.22 Olivier SCHWARTZ Role of DC-SIGN/DC209 in Mycobacterium tuberculosis attachment and entry into human dendritic cells and role of lipoarabinomannan (LAM) as a DC-SIGN ligand
01.24 Hélène MUNIER-LEHMANN M. tuberculosis thymidylate kinase (TMPK) inhibitors: use in the development of new antitubercular drugs

Therapeutics vaccines

Therapeutics vaccines
D.I. n° Inventor Title
03.04 Sylvie BAY Phosphorylcholine-glycoconjugates and their synthesis : diagnostic and therapeutic applications
00.69 Alice DAUTRY-VARSAT Methods for prevention or treatment of Chlamydia infection
00.59 Claude LECLERC B. pertussis adenylate cyclase-activating peptide receptor and its use in screening for immunologically/pharmacologically active molecules

Therapeutics viral

Therapeutics viral
D.I. n° Inventor Title
09.20 Rajeekumar TAWAR X-ray structure of a (Respiratory Syncytial Virus) Nucleoprotein-RNA template-like assembly
09.31 Pierre-Olivier VIDALAIN Characterization of two chemical compounds showing a broad-spectrum antiviral activity
08.47 Pierre-Olivier VIDALAIN A mammalian cell-based screening assay to identify molecules that stimulate
IFN- alpha/ ßeta target genes

04.87

Françoise COLBERE-GARAPIN Viral genome oligoribonucleotide homologs for treatment of persistant viral infections
04.32 Ralf ALTMEYER Optimized genes for increased SARS Co V Spike protein expression
04.14 Frédéric TANGY Infectious flavivirus pseudo-particles containing functional prM-E envelop proteins
04.12  Philippe DESPRES
Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis
03.68 Hervé BOURHY Identification of a peptide motif of lyssavirus matrix protein involved in the induction of apoptosis : therapeutic applications
03.60 Nicole TANDEAU DE MARSAC Use of microvirins against viral infection
02.63 Florence COLBERE-GARAPIN Transfer of viral genome and/or viral cell receptor oligoribonucleotide homologs for the inhibition of picornavirus expression
02.45 Philippe DESPRES Induction of protective immune response involving flavivirus membrane M protein ectodomain exposure to plasma membrane
02.44 Pierre LAFAYE Monoclonal antibodies directed against calreticulin: diagnostic and intracellular targeting applications
01.68 Fernando ARENZANA-SEISDEDOS Human langerin is the principal receptor expressed by Langerhans cells permitting HIV envelope glycoprotein binding
01.52 François LEMONNIER Use of RNA for the induction of antiviral response
96.31 Jean-Louis VIRELIZIER Human SDF chemokine and its application as a HIV therapeutic

Vaccines

Vaccines
D.I. n° Inventor Title
09.20 Rajeekumar TAWAR X-ray structure of a (Respiratory Syncytial Virus) Nucleoprotein-RNA template-like assembly
09.08 Laurence MULARD Rationally designed liposome-based diepitope constructs as glycoimunogens and their use in vaccine compositions : application to Shigella flexneri serotype 2a
05.49 Sylvie BAY MUC6-Tn glycoconjugates mimicking cancer cells: applications to anti-tumor immunotherapy
05.38 Ralf ALTMEYER Purified trimeric S protein as vaccine against Severe Acute Respiratory Syndrome virus infections
05.37 Marie-Louise MICHEL Identification of T-cell epitopes derived from HBSP protein of HBV
05.12 Shirley LONGACRE Recombinant Plasmodium Falciparum merozoite surface proteins 4 and 5 their use
04.29 Yves RIVIERES T-cell immunogenicity of protein core+ 1 in chronic carriers of hepatitis C virus. Therapeutic and/or vaccine applications
04.12 Philippe DESPRES Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis
04.02 François LEMONNIER Evaluation of the protective capacity of cellular immune response completely restricted to human HLA alleles induced in vivo in the absence of murine response competition in mice doubly transgenic for HLA-A2/HLA-DR1 and double knockout for H-2 class 1&II (b2m°/°/lab°/°KO) against viral challenge. Vaccine and immunology applications for preclinical development of new vaccines.
03.53 Claude LECLERC Synthetic glycopeptide vaccines : applications in anti-tumoral immunotherapy
03.44 Pierre DRUILHE Gene family cluster encoding proteins targeted by antibodies effective at killing Plasmodium falciparum erythrocytic stages
03.43 Claude LECLERC Identification of the Bordetella pertussis adenylate cyclase domain that interacts with its receptor the integrin (CD11b/CD18)
03.19 Steward COLE Use of Mycobacterium tuberculosis RD1 in vaccine applications
02.95 Brigitte GICQUEL BCG strain with an inactivating mutation of the ureC gene
02.91 Annette MARTIN An infectious chimeric GB virus B containing the core domain III of the HepatitisC virus (HCV) ires that is infectious and causes hepatitis in tamarins : a new animal model for HCV studies
02.83 Catherine TRANSY Molecular tools for the selection of human primary hepatocytes infected with hepatitis C virus (HCV): use in the development of novel antiviral molecules and in the study of molecular interactions between HCV and host cell
02.24 Philippe DESPRES Yellow fever molecular determinant M-36 and its role in the attenuation of various anti-amaril vaccine strains through modulation of proapototic activity of hepatotropic flavirirus
02.21 Philippe DESPRES Analysis of the immune capacities of recombinant measles viruses expressing Env and NS1 from yellow fever virus
02.20 Frédéric TANGY Recombinant measles viruses expressing the native envelope glycoprotein of HIV1 clade B or envelopes with deleted variable loops induce humoral and cellular immune responses
02.19 Frédéric TANGY Production of an infectious cDNA of the Schwarz strain of measles vaccine
02.06 Pierre DRUILHE Novel Plasmodium falciparum antigen DG 571 for the induction of protection against challenge infection with Plasmodium sporozoite
01.87 Armand BERNEMAN Potential adjuvant effect of T. cruzi proline racemase (TcPA45)
01.65 Claude LECLERC Use of viral pseudo-particles (PPV-PLPS) for targeting and activation of dendritic cells and their adjuvant effect
01.63 Antoine DANCHIN Partial sequencing and annotation of Penicllium marneffei genome
01.55 Pierre LANGLADE-DEMOYEN News HIV1 epitopics peptides
01.54 Claude LECLERC B. pertussis adenylatecyclase receptor: use in screening for immunologically/pharmacologically active molecules
01.40 Frédéric TANGY Generation of an Infectious cDNA corresponding to the antigenome of the Schwarz Vaccine Strain of Measles Virus
01.31 Pierre DRUILHE Identification of two novel Plasmodium falciparum antigens involved in host response to the pre-erythrocyte stages of the parasite
01.24 Hélène MUNIER-LEHMANN M. tuberculosis thymidylate kinase (TMPK) inhibitors: use in the development of new antitubercular drugs
01.23 Jean-Michel FOURNIER Novel vaccine composition inducing protective antibodies against cholera 
01.13 Pierre DRUILHE Phosphatase A2 protein binding sites for HIV-1 Vpr protein and parasite Theileria protein kinase CK2-alpha: two new targets for viral, parasitic or tumoral indications
00.80 Hechmi LOUZIR Vaccine against leishmaniasis using virulence antigen P55 gene 
00.31/98.20 Philippe MARLIERE In vivo production of proteins chemically diversified by incorporation of non-conventional amino acids: useful in vaccines, therapy, diagnosis and biocynthesis 
00.25 Gilles MARCHAL Immunogenic glycopeptides derived from Mycobacterium tuberculosis: diagnostic and vaccine applications
99.75 Michèle BOULOY Attenuated Rift Valley Fever Virus: human and veterinary vaccine applications 
99.44 Pierre DRUILHE Mucosal immunization using lipid-tailed peptides without adjuvant
98.51 Stewart COLE Deleted sequences in M. bovis BCG/M. bovis or M. tuberculosis genomes: diagnostic and vaccine applications
98.31 Brigitte GICQUEL New sequences of M. tuberculosis and the identification of associated genes
96.61/99.62 Claude LECLERC MAG: A new family of optimized synthetic glycopeptidic vaccines with high therapeutic activity
96.42/95.33 Claude LECLERC Recombinant parvovirus-like particles for inducing cytotoxic T-cell response: use in antiviral and antitumoral drugs or vaccines
96.26 Armelle PHALIPON Novel immunogenic polypeptides for the induction of protective immune response against pathogenic microorganisms and method for their production
91.13 Gilles MARCHAL Mycobacterium Proteins and their applications (naxi test)

Veterinary medecine

Veterinary medecine
D.I. n° Inventor Title

04.14

Frédéric TANGY Infectious flavivirus pseudo-particles containing functional prM-E envelop proteins

04.12

Philippe DESPRES Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis
03.19 Steward COLE Use of Mycobacterium tuberculosis RD1 in vaccine applications
02.97 Daniel GONZALES-DUNIA 2’Fluoro-2’-deoxycytidine inhibits Borna Disease Virus Replication and Spread
02.28 Stewart COLE Improved vaccines for the prevention of tuberculosis infection in animals
01.13 Pierre DRUILHE Phosphatase A2 protein binding sites for HIV-1 Vpr protein and parasite Theileria protein kinase CK2-alpha: two new targets for viral, parasitic or tumoral indications
00.20 Michel Y. POPOFF Un nouveau traitement préventif de la salmonellose chez l’animal
00.04 Nicole GUISO-MACLOUF Antigenic variants of pertactin in Bordetella: diagnostic and immunogenic applications in veterinary field
99.75 Michèle BOULOY Attenuated Rift Valley Fever Virus: human and veterinary vaccine applications